Cat. No. 3432
Chemical Name: 1-Benzoyl-2-[[trans-4-[[[[2-nitro-4
Biological ActivityPotent neuropeptide Y (NPY) Y5 receptor antagonist (IC50 values are 5.4, > 1000, > 10 000 and > 10 000 nM at Y5, Y1, Y2 and Y4 receptors respectively) that displays no affinity for a wide range of other receptors. Does not produce a conditioned taste aversion, suppress sodium appetite or cause pica in rats. Significantly inhibits NPY-induced feeding but not through blockade of Y5 receptors.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Kamiji and Inui (2007) Neuropeptide Y receptor selective ligands in the treatment of obesity. 28 664.
Beauverger et al (2005) Functional characterization of human neuropeptide Y receptor subtype 5 specific antagonists using a luciferase reporter gene assay. Cell.Signal. 17 489. PMID: 15601626.
Della-Zuana et al (2004) A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. Int.J.Obes. 28 628.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses S 25585 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: S 25585, supplier, Potent, selective, NPY, Y5, antagonists, neuropeptide, Receptors, S25585, neuropeptides, Tocris Bioscience, NPY Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonistNeuropeptide S (Mouse)
Potent endogenous neuropeptide S receptor (NPSR) agonistML 382
MrgX1 (SNSR4) positive allosteric modulatorK-(D-1-Nal)-FwLL-NH2
High affinity and potent ghrelin receptor inverse agonistNeuropeptide S (Rat)
Potent endogenous neuropeptide S receptor agonistNeuropeptide S (human)
Potent endogenous neuropeptide S receptor agonist
October 30 - November 3, 2016
Boston, MA, USA